Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy

Published:2020-06 Issue: Volume:49 Page:101434
ISSN:1044-5323
Container-title:Seminars in Immunology
language:en
Short-container-title:Seminars in Immunology

Author:

Meng Xianhui,Wu Xiaoyan,Zheng Yuyuan,Shang Kai,Jing Ruirui,Jiao Peng,Zhou Chun,Zhou Jing,Sun Jie

Funder

National Natural Science Foundation of China

Zhejiang Provincial Natural Science Foundation

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference75 articles.

1. Cancer immunotherapy: harnessing the immune system to battle cancer;Yang;J. Clin. Invest.,2015

2. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy;Khalil;Nat. Rev. Clin. Oncol.,2016

3. Immune checkpoint inhibitors: recent progress and potential biomarkers;Darvin;Exp. Mol. Med.,2018

4. The pharmacology of second-generation chimeric antigen receptors;van der Stegen;Nat. Rev. Drug Discov.,2015

5. Chimeric antigen receptor therapy;June;N. Engl. J. Med.,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a pro-protein synthesis osteosarcoma subtype for predicting prognosis and treatment;Scientific Reports;2024-07-16

2. Application of calcium overload-based ion interference therapy in tumor treatment: strategies, outcomes, and prospects;Frontiers in Pharmacology;2024-02-15

3. Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency;Molecular Therapy;2023-01

4. Activation of Mechanosensitive Ion Channels by Ultrasound;Ultrasound in Medicine & Biology;2022-10

5. Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review;Journal of Experimental & Clinical Cancer Research;2022-07-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3